Trial Profile
Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+).
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Antineoplastics
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 25 Mar 2013 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
- 01 Apr 2011 Planned initiation date changed from 1 Nov 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 23 Oct 2010 New trial record